Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
SINGAPORE, April 17, 2018 -- ASLAN Pharmaceuticals (ASLAN) (6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced the presentation of new data from a study of the use of varlitinib in hepatocellular carcinoma (HCC) at the American Association for Cancer Research (AACR) 2018 Annual Meeting in Chicago, Illinois.
| Details of the poster are as below: | ||
| Session: | Experimental and Molecular Therapeutics | |
| Poster #: | 3992 / 26 | |
| Section: | 41 | |
| Title: | Varlitinib demonstrates tumor regression and vessel normalization in ErbB-dependent and mutated beta-catenin hepatocellular carcinoma patient-derived xenograft model | |
The pre-clinical study was conducted in collaboration with the National Cancer Centre Singapore (NCCS) and was led by Professor The Huynh Hung, Principal Investigator at NCCS’ Laboratory of Molecular Endocrinology. The study was designed to demonstrate the efficacy of varlitinib in HCC patient-derived xenograft (PDX) models and to study the molecular mechanisms of varlitinib-mediated tumor suppression and its anti-angiogenic potential. In addition, the study sought to identify gene signatures associated with efficacy of varlitinib by transcriptome and gene expression analyses.
About varlitinib (ASLAN001)
Varlitinib (ASLAN001) is a highly potent, oral, reversible, small molecule pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2 and HER4. These receptors can be mutated or overexpressed in many tumors, which can cause excessive proliferative activity and uncontrolled growth. Therefore, by inhibiting the activation of the HER receptors, varlitinib could inhibit proliferation and control tumor growth. Varlitinib is currently being studied in gastric, biliary tract, breast and colorectal cancers. Varlitinib has been granted orphan drug designation in the United States for gastric cancer and cholangiocarcinoma, a sub-type of biliary tract cancer, and was awarded orphan drug designation for the treatment of biliary tract cancer by the Ministry of Food and Drug Safety in South Korea.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (ASLAN, 6497.TT) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. ASLAN targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. Led by a senior management team with extensive experience in global and regional development and commercialization, ASLAN is headquartered in Singapore and has offices in Taiwan and China. ASLAN’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. ASLAN’s partners include Array BioPharma, Bristol-Myers Squibb, Almirall and CSL. For additional information please visit www.aslanpharma.com.
Media and IR contacts Chris Fang ASLAN Pharmaceuticals Tel: +886 2 2758 3333 Email: [email protected] Emma Thompson / Stephanie Tan Spurwing Communications Tel: +65 6340 7287 Email: [email protected] Robert H Uhl Westwicke Partners Tel: +1 858 356 5932 Email: [email protected]
